MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

Rhea-AI Summary

MaxCyte, a commercial cell-engineering firm, will announce its Q3 2021 financial results on November 10, 2021, after U.S. market close. The management will host a conference call at 4:30 p.m. ET to discuss results. With 20 years of experience, MaxCyte offers proprietary Flow Electroporation technology for cell engineering, supporting the growing cell therapy market with its ExPERT platform, including various instruments and software protocols. This information is crucial for shareholders and potential investors in gauging financial performance and future growth prospects.

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10^th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 5098687. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

FAQ

When will MaxCyte release its Q3 2021 financial results?

MaxCyte will release its Q3 2021 financial results on November 10, 2021, after U.S. market close.

What time is the conference call for MaxCyte's Q3 2021 earnings?

The conference call for MaxCyte's Q3 2021 earnings will be at 4:30 p.m. Eastern Time on November 10, 2021.

How can I access the conference call for MaxCyte's financial results?

To access the conference call, call (844) 679-0933 for domestic or (918) 922-6914 for international callers, using Conference ID: 5098687.

What technology does MaxCyte specialize in?

MaxCyte specializes in cell-engineering technologies, particularly its Flow Electroporation platform and ExPERT platform for cell therapy.

Where can I find the webcast of MaxCyte's conference call?

The live and archived webcast of the conference call will be available in the 'Events' section of the MaxCyte website.